Nicotinamide riboside,
does it really help with Improvement of usual gait speed in frail older adults?
research showsAs of 2026-09-15, a direct between-group result was not verified showing whether planned oral NR 2000 mg/day for 52 weeks increases usual gait speed (m/s) versus placebo in community-dwelling adults aged at least 75 with a Fried Frailty Phenotype score of at least 3. The current grade is ? and no numerical score is assigned. This is not a finding of no effect or a declaration of worldwide absence of evidence. [S01][S02]
ads claimThis paragraph explains claim boundaries rather than quoting a particular company’s advertisement. A rise in NAD or walking results for the different molecule NMN do not establish that NR improves usual gait speed in frail older adults. NR was not automatically equated with nicotinamide, nicotinic acid, NMN or combination products. [S08][S13][S14][S17]
Four separate assessment dimensions
| Effect direction and size | As of 2026-09-15, a direct between-group result was not verified showing whether planned oral NR 2000 mg/day for 52 weeks increases usual gait speed (m/s) versus placebo in community-dwelling adults aged at least 75 with a Fried Frailty Phenotype score of at least 3. The current grade is ? and no numerical score is assigned. This is not a finding of no effect or a declaration of worldwide absence of evidence. [S01][S02] |
|---|---|
| Evidence certainty | The current ? is the stage-0 current value for failure to verify a directly eligible result within the logged search. The original calculator’s no_human_study compatibility flag is explicitly scoped to this meaning; it does not claim that human NR research does not exist. Plans or indirect findings were not counted as R1/R2, nor was another population’s non-significance transported as D/F. Remaining result-rating axes and a numerical score were not invented. |
| Applicability | Community-dwelling adults aged at least 75, Fried Frailty Phenotype at least 3; baseline gait speed and nutrition unverified; Planned 2000 mg/day; per-dose amount, frequency, escalation and salt conversion basis unverified; Planned 52 weeks; actual exposure and post-treatment follow-up unverified |
| Safety | Caution does not mean that NR harm has been established. Adverse events, discontinuations and long-term safety for this frail population and the planned 2000 mg/day for 52 weeks were not verified. EFSA’s assessment of specified NR chloride and 300 mg/day use in healthy adults does not guarantee safety for this higher-dose, longer plan. Research doses are not personal dosing advice; review the product and concomitant medicines with a clinician. Nicotinic-acid flushing and hepatic risks were not copied as proven adverse effects of the different molecule NR. [S01][S02][S11][S12] |
? is the current value that no direct eligible result for the exact question was verified in the logged search. It is not no effect or worldwide absence of research, and no numerical score is invented.
Useful facts when choosing a product
- This is an oral NR supplementation claim. Salt, crystal form, brand, manufacturer, purity, batch and release form are unverified. [S01][S02]
- 2000 mg/day and 52 weeks are boundaries from a public plan; actual adherence, frequency, escalation and common care are unverified. [S01][S02]
- NIAGEN and NR chloride information from another trial was not copied into this plan’s product identity. [S08]
Chamgap Semantic Classification Code
Permanent code issued
S.nicotinamide-riboside.oral.frail-older-adults-usual-gait-speed.improve.placeboSubstances and nutrients > Nicotinamide riboside > Oral > Usual gait speed in frail older adults > Improvement claim > Placebo
Technically bound to the ChatGPT-fixed current-value question of planned NR 2000 mg/day for 52 weeks versus placebo for improvement in usual-gait-speed change (m/s) among adults aged at least 75 with Fried score at least 3. No verified direct eligible result and unverified salt, product, protocol and safety details remain in multidimensional fields and revision history. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Nicotinamide riboside (NR; salt and product details unverified) |
| Source or part used | Manufacturing source unverified |
| Formulation or processing | NR-versus-placebo plan; salt, crystal, product, dosage and release form unverified |
| Route | Oral |
| Dose | Planned 2000 mg/day; per-dose amount, frequency, escalation and salt conversion basis unverified |
| Duration | Planned 52 weeks; actual exposure and post-treatment follow-up unverified |
| Population | Community-dwelling adults aged at least 75, Fried Frailty Phenotype at least 3; baseline gait speed and nutrition unverified |
| Effect or condition | Improvement in usual gait speed |
| Primary endpoint | Between-group difference in baseline-to-week-52 usual-gait-speed change (m/s); page endpoint, actual trial hierarchy and habitual-pace protocol unverified |
| Comparator | Placebo (exact composition, matching and common care unverified) |
| Duplicate-detection key | nicotinamide-riboside[salt-unverified]|oral|2000-mg-day-planned|52-weeks|community-age-ge75-fried-ge3|usual-gait-speed-change-mps|placebo[composition-unverified] |
What the research actually shows
The closest NADage plan anchors the population, dose and duration, but usual-speed raw values, changes, between-group estimate, CI, analysis denominator and measurement protocol remain unverified. The NR-VETS institutional excerpt describes non-frail/prefrail participants with Fried scores below 3. MCI, healthy-aging and peripheral-artery-disease studies were not pooled as results for this frailty definition. [S01][S02][S03][S04][S05][S08][S09]
Why this is classified as ?
The current ? is the stage-0 current value for failure to verify a directly eligible result within the logged search. The original calculator’s no_human_study compatibility flag is explicitly scoped to this meaning; it does not claim that human NR research does not exist. Plans or indirect findings were not counted as R1/R2, nor was another population’s non-significance transported as D/F. Remaining result-rating axes and a numerical score were not invented.
Counterpoint. Negative and non-significant adjacent findings are distinguished. Walking-speed p=0.0402 for placebo and p=0.4698 for NR in Orr’s MCI abstract are within-group changes, not a between-group test. Martens’ healthy-aging crossover also reported no overall motor improvement, but results in participants with good physical function were not counted as repeated refutation in this frail population. [S05][S08]
Rejudgment record. No directly eligible result verified; distinct from no effect — original calculator stage 0 + explicitly scoped current-value policy
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests Case application: P: usual gait speed is a patient functional endpoint, but no exact direct result was verified, so the remaining axes were not inferred. |
Review performed and remaining limitations
A direct eligible between-group usual-gait-speed result, actual enrolled/completed/analysis counts, salt/product/formulation, habitual-speed protocol, placebo composition and 2000 mg/day for 52 weeks safety remain unverified.
Search scope and limitations. R01-013 verified package: search_log.json; selection_log.json; sources.json
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| NADage | Randomized double-blind placebo-controlled plan; the complete registry and results were not verified. | 100 planned. Actual enrolled, randomized, completed and usual-gait-speed analysis counts are unverified. | Funding information was present on the investigator page, but independence was not scored because no direct eligible result was verified. | Planned 6-minute walk with concurrent sensor gait assessment; equivalence to usual short-course gait speed is unverified. | The population and planned dose are the closest match, but no target between-group usual-gait-speed result was verified. | Closest protocol context only; not scored as direct effect evidence. |
| NR-VETS | Study context from an official institutional index; complete registration, protocol and results are unverified. | The actual analysis denominator for the target question is unverified. | Funding and conflicts were not scored because no direct result for the target question was verified. | Gait testing mentioned; hierarchy, protocol and results unverified. | Non-frail or prefrail participants (Fried <3), mismatching the target frail population; target result unverified. | Excluded from direct evidence because of population mismatch. |
| Orr MCI trial | Placebo-controlled trial in mild cognitive impairment; access to complete methods and tables was limited. | 20 completers reported. The usual-gait-speed analysis denominator and total randomized count are unverified. | Not used for the page independence axis because the population is ineligible. | Walking speed was a secondary physical test; habitual-pace protocol and between-arm m/s estimate are unverified. | Within-arm p=0.0402 for placebo and p=0.4698 for NR. Within-arm p-values are not a between-group effect estimate. | Indirect evidence with population and analysis-format mismatch. |
| Martens healthy-aging crossover | Crossover trial in healthy middle-aged and older adults. | Not an analysis count for usual gait speed in the target frail population. | Not used for the page independence axis because the population and regimen are ineligible. | Exploratory motor battery; no overall motor-function effect reported. | Healthy participants with good baseline physical function differ from the target frail population. | Indirect evidence with population and regimen mismatch. |
| NICE PAD trial | Randomized clinical trial in 90 adults with peripheral artery disease. | 90 randomized overall; not an analysis denominator for usual gait speed in the target frail population. | Not used for the page independence axis because this is not a direct result for the target question. | Six-month change in 6-minute walk distance (m); WIQ speed is a self-report score. | Arithmetic between-group 6-minute-walk difference +17.6 m, reported one-sided 90% CI lower bound +1.77 m and P=0.08; not usual gait speed in m/s. | Positive adjacent result, but not transported as direct evidence because endpoint and population differ. |
Receipt — 15 References
Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none
Cite this verdict
[Chamgap] NR × usual gait speed in frail older adults — Evidence Grade ?. 15 cited sources checked. Source: https://chamgap.com/en/verdicts/sports/oral-nicotinamide-riboside-frail-older-adults-usual-gait-speed/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.